Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Fei-Yu Diao

doi:10.1055/s-0041-1736239

Global Medical Genetics, Table of Contents

CC BY 4.0 · Glob Med Genet 2022; 09(01): 001-003
DOI: 10.1055/s-0041-1736239

Editorial

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Fei-Yu Diao

¹Department of General Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China

› Author Affiliations

Abstract

Full Text

References

References
1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70 (01) 7-30
2 Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Commun (Lond) 2019; 39 (01) 22
3 Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020; 40 (05) 205-210
4 André F, Ciruelos E, Rubovszky G. et al; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019; 380 (20) 1929-1940
5 Ding S, Chen X, Shen K. Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun (Lond) 2020; 40 (08) 329-344
6 Rugo HS, Rumble RB, Macrae E. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34 (25) 3069-3103
7 Guan X, Ma F, Li C. et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun (Lond) 2019; 39 (01) 1
8 Slamon DJ, Neven P, Chia S. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018; 36 (24) 2465-2472
9 Harbeck N, Iyer S, Turner N. et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 2016; 27 (06) 1047-1054
10 Sobhani N, Roviello G, Corona SP. et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem 2018; 119 (06) 4287-4292
11 Baselga J, Im SA, Iwata H. et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18 (07) 904-916
12 André F, Ciruelos EM, Juric D. et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021; 32 (02) 208-217
13 Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002; 7 (Suppl. 06) 13-19
14 Didwaniya N, Tanco K, de la Cruz M, Bruera E. The need for a multidisciplinary approach to pain management in advanced cancer: a clinical case. Palliat Support Care 2015; 13 (02) 389-394
15 Ciruelos EM, Rugo HS, Mayer IA. et al. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1. J Clin Oncol 2021; 39 (18) 2005-2015